Rakuten Investment Management Inc. Purchases 39,111 Shares of Stryker Corporation $SYK

Rakuten Investment Management Inc. lifted its position in Stryker Corporation (NYSE:SYK) by 634.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 45,273 shares of the medical technology company’s stock after acquiring an additional 39,111 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Stryker were worth $15,959,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker in the 4th quarter worth $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker in the 4th quarter worth about $27,000. DJE Kapital AG purchased a new position in shares of Stryker in the 4th quarter worth about $28,000. Finally, Strive Asset Management LLC purchased a new position in shares of Stryker in the 3rd quarter worth about $30,000. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SYK shares. Citigroup cut their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Canaccord Genuity Group cut their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. UBS Group cut their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Evercore set a $355.00 price target on Stryker in a research report on Friday, May 1st. Finally, Barclays cut their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $395.33.

Stryker Trading Down 1.4%

Shares of Stryker stock opened at $307.86 on Tuesday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a market cap of $118.02 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 1.97 and a beta of 0.78. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $315.93 and its 200-day moving average price is $343.32.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last three months. 4.60% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.